The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells

Journal of Immunotherapy

Volumn 32, Issue 1, 2009, Pages 22-28

  Lee, Sung Yong ^a   Choi, Hye Kyoung ^a   Lee, Kyoung Ju ^a   Jung, Jin Yong ^a   Hur, Gyu Young ^a   Jung, Ki Hwan ^b   Kim, Je Hyeong ^b   Shin, Chol ^b   Shim, Jae Jeong ^a   In, Kwang Ho ^c   Kang, Kyung Ho ^a   Yoo, Se Hwa ^c  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Korea University   (South Korea)

Author keywords

COX 2; Foxp3; IDO; Immune tolerance; PGE2; Regulatory T cell

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; INDOLEAMINE 2,3 DIOXYGENASE; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; CYCLOOXYGENASE 2 INHIBITOR; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REGULATORY T LYMPHOCYTE; TUMOR VOLUME; ANIMAL; BLOOD; C57BL MOUSE; DENDRITIC CELL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; DENDRITIC CELLS; DINOPROSTONE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; PYRAZOLES; SULFONAMIDES; T-LYMPHOCYTES, REGULATORY;

EID: 65549154975     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31818ac2f7     Document Type: Article

References (28)

1. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725-729.
2. von Bergwelt-Baildon MS, Popov A, Saric T, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglan-din E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 2006; 108:228-237.
3. Akasaki Y, Liu G, Chung NH, et al. Induction of a CD4+T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol. 2004;173:4352-4359.
4. +T cells. J Immunol. 2005; 175:1483-1490.
5. + T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res. 2006;66:1114-1122.
6. + T regulatory cell activities in lung cancer. Cancer Res. 2005;65:5211-5220.
7. Corbett TH, Griswold DP Jr, Roberts BJ, et al. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer. 1977;40(5 suppl):2660-2680.
8. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942-949.
9. Pisarra P, Mortarini R, Salvi S, et al. High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition. Cancer Immunol Immunother. 1999;48:39-46.
10. Echchakir H, Vergnon I, Dorothee G, et al. Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol. 2000;12:537-546.
11. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-213.
12. Svennevig JL, Lunde OC, Holter J, et al. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer. 1984;49: 375-377.
13. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1 107 1 111.
14. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189:1363-1372.
15. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. Jq Clin Invest. 2001; 108:15-23.
16. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005; 106:2375-2381.
17. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabo-lism. Faseb J. 1991;5:2516-2522.
18. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269-1274.
19. Moffett JR, Espey MG, Namboodiri MA. Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system. Cell Tissue Res. 1994;278: 461-469.
20. Sayama S, Yoshida R, Oku T, et al. Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc Natl Acad Sci USA. 1981;78:7327-7330.
21. + T regulatory cells. Blood. 2007;109:2871-2877.
22. Wobser M, Voigt H, Houben R, et al. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3- dioxygenase expression. Cancer Immunol Immunother. 2007;56: 1017-1024.
23. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299:1057-1061.
24. + T regulatory cells. Nat Immunol. 2003; 4:337-342.
25. Shaik MS, Chatterjee A, Jackson T, et al. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer. 2006; 118:396-404.
26. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 2000;164: 361-370.
27. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000;164(3 Pt 1):820-825.
28. Yao R, Rioux N, Castonguay A, et al. Inhibition of COX-2 and induction of apoptosis: two determinants of nons-teroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res. 2000;26: 731-742.